Snapshot from Jul 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / AnaCardio AC01 GOAL-HF1 Study Published
Tech medical breakthrough

AnaCardio AC01 GOAL-HF1 Study Published

Analysis based on 13 articles · First reported Jun 24, 2026 · Last updated Jun 28, 2026

Sentiment
70
Attention
4
Articles
13
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive results and publication in The Lancet for AnaCardio's drug AC01 are expected to significantly boost investor confidence in AnaCardio and the broader biopharmaceutical sector focused on heart failure treatments. This could lead to increased investment in AnaCardio and similar companies, as AC01 represents a potential breakthrough in a market with high unmet medical needs.

pharmaceutical biotechnology
Event Summary

AnaCardio, a clinical-stage biopharmaceutical company, announced the publication of positive results from its Phase 1b/2a GOAL-HF1 study for AC01 in The Lancet. AC01, an oral calcium-sensitising contractile agent, demonstrated a favorable safety and tolerability profile, along with rapid and sustained improvements in cardiac output, structure, and function in patients with heart failure with reduced ejection fraction (HFrEF). This scientific validation supports AnaCardio's decision to advance AC01 into Phase 2b clinical development, with CEO Patrik Strömberg and founder Lars Erik Lund emphasizing the drug's potential to address a leading cause of death and hospitalization worldwide.

Key Actions
90 AnaCardio advanced AC01
30 United States — Food and Drug Administration provided scientific advice AnaCardio
30 European Union — European Medicines Agency provided scientific advice AnaCardio
Entities Involved
priv
AnaCardio
AnaCardio announced the publication of positive Phase 1b/2a GOAL-HF1 study results for its drug AC01 in The Lancet, validating its potential as a treatment for heart failure with reduced ejection fraction (HFrEF) and supporting its advancement to Phase 2b clinical development. This is a significant milestone for the company.
Importance 100.0 Sentiment 75.0
oth
AC01
AC01 is AnaCardio's lead drug candidate, an oral calcium-sensitising contractile agent, which showed a favorable safety profile and improvements in cardiac function in the GOAL-HF1 study, indicating its potential as a chronic treatment for HFrEF patients.
Importance 95.0 Sentiment 70.0
per
Patrik Strömberg
Patrik Strömberg, CEO of AnaCardio, commented on the significance of the GOAL-HF1 results publication, highlighting AC01's potential and supporting its rapid advancement.
Importance 40.0 Sentiment 0.0
per
Lars Erik Lund
Professor Lars Erik Lund, Cardiologist at Karolinska University Hospital and Founder of AnaCardio, provided expert commentary on the encouraging efficacy and safety profile of AC01.
Importance 40.0 Sentiment 0.0
priv
Helsinn
AC01 was in-licensed by AnaCardio from Helsinn.
Importance 10.0 Sentiment 0.0
govactor
European Union — European Medicines Agency
AnaCardio received positive scientific advice from the European Union — European Medicines Agency regarding the development path for AC01.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
AnaCardio received positive scientific advice from the United States — Food and Drug Administration regarding the development path for AC01.
Importance 10.0 Sentiment 0.0
Relationships
European Union — European Medicines Agency related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.